Content about Paracetamol

WASHINGTON — The Consumer Healthcare Products Association on Wednesday announced plans to convert liquid pediatric acetaminophen products to just one concentration.

This voluntary change means the current children’s strength of liquid acetaminophen (160 mg/5 mL) will become the only liquid concentration available for all children younger than 12 years, and the current concentrated infant drops no longer will be sold.

MORRISTOWN, N.J. — Actavis last week named Lisa Buono to lead its over-the-counter drug division as part of the company’s strategic expansion of the division.

As director of OTC, Buono will oversee the division’s day-to-day operations and will focus on identifying and capitalizing on new product opportunities. Actavis manufactures and distributes numerous nonprescription liquids, creams and ointments sold under the Actavis label and its customers’ own brands, as well as FeverAll brand acetaminophen suppositories.

NASHVILLE, Tenn. — The Food and Drug Administration has approved a new formulation of a drug for treating acetaminophen poisoning.

Cumberland Pharmaceuticals announced Thursday that the agency had approved a version of Acetadote (acetylcysteine) injection that does not contain preservatives or stabilization and chelating agents, and will replace the currently marketed version. The drug originally was approved in 2004.

SILVER SPRING, Md. A drug maker will pull a common prescription painkiller from the market following the release of clinical data that it could cause heart problems.

IRVINGTON, N.Y. Prestige Brands has expanded its Little Remedies product line with a new analgesic for infants, toddlers and children.

New Little Fevers is concentrated infant drops with acetaminophen and indicated for the treatment of temporary fever and minor aches and pains which may be associated with the common cold, flu, headache, sore throat or toothache. The product is specially formulated to provide small concentrated doses for easier administration, Presitge Brands said.

NEW YORK Sales of liquid Tylenol formulations, both adult and children, totaled $104.5 million across food, drug and mass (minus Walmart) for the 52 weeks ended May 17, according to Information Resources Inc. Internal analgesics tablet sales of Tylenol SKUs (across the top 20 brands) generated another $480.9 million. That’s more than $500 million in annual revenue, not including Walmart, potentially impacted by a future Food and Drug Administration decision. That’s not even representative of all acetaminophen sales.